JP2004002481A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004002481A5 JP2004002481A5 JP2003315495A JP2003315495A JP2004002481A5 JP 2004002481 A5 JP2004002481 A5 JP 2004002481A5 JP 2003315495 A JP2003315495 A JP 2003315495A JP 2003315495 A JP2003315495 A JP 2003315495A JP 2004002481 A5 JP2004002481 A5 JP 2004002481A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic composition
- antibody
- composition according
- antigen
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001225 therapeutic effect Effects 0.000 claims 28
- 239000000427 antigen Substances 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 230000005745 host immune response Effects 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 238000001727 in vivo Methods 0.000 claims 6
- 230000037396 body weight Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 230000024932 T cell mediated immunity Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940124447 delivery agent Drugs 0.000 claims 2
- 230000028996 humoral immune response Effects 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
Images
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003315495A JP4247783B2 (ja) | 2003-09-08 | 2003-09-08 | 免疫応答を惹起するための、多数エピトープ含有抗原の再構成法および組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003315495A JP4247783B2 (ja) | 2003-09-08 | 2003-09-08 | 免疫応答を惹起するための、多数エピトープ含有抗原の再構成法および組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000200702A Division JP2001055341A (ja) | 2000-01-01 | 2000-07-03 | 免疫応答を惹起するための、多数エピトープ含有抗原の再構成法および組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007233849A Division JP2007320969A (ja) | 2007-09-10 | 2007-09-10 | 免疫応答を惹起するための、多数エピトープ含有抗原の再構成法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004002481A JP2004002481A (ja) | 2004-01-08 |
| JP2004002481A5 true JP2004002481A5 (https=) | 2005-05-26 |
| JP4247783B2 JP4247783B2 (ja) | 2009-04-02 |
Family
ID=30439017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003315495A Expired - Lifetime JP4247783B2 (ja) | 2003-09-08 | 2003-09-08 | 免疫応答を惹起するための、多数エピトープ含有抗原の再構成法および組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4247783B2 (https=) |
-
2003
- 2003-09-08 JP JP2003315495A patent/JP4247783B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003519096A5 (https=) | ||
| Garbe et al. | Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting | |
| JP2021519076A5 (https=) | ||
| JP2004512262A5 (https=) | ||
| Phillips et al. | Influence of phospholipid composition on antibody responses to liposome encapsulated protein and peptide antigens | |
| JP2012046518A5 (https=) | ||
| HRP20151172T1 (hr) | Sastavi i postupci za dijagnosticiranje i lijeäśenje raka | |
| JP2003528805A5 (https=) | ||
| JP2006506441A5 (https=) | ||
| CN101969980A (zh) | 抗-EDb纤连蛋白抗体-IL-2融合蛋白与结合至B细胞、B祖细胞和/或它们的癌性对应物的分子的组合物 | |
| JP2007524613A5 (https=) | ||
| Niaz et al. | Prostate-specific membrane antigen based antibody-drug conjugates for metastatic castration-resistance prostate cancer | |
| WO2002032923A3 (en) | Improved formulations using heat shock/stress protein-peptide complexes | |
| JPWO2019191728A5 (https=) | ||
| Zhao et al. | Polymersome-enabled brain codelivery of STAT3 siRNA and CpG oligonucleotide boosts chemo-immunotherapy of malignant glioma | |
| US20190216907A1 (en) | Compositions for and methods of treating and preventing cancer targeting tumor associated carbohydrate antigens | |
| ES2991384T3 (es) | Composición farmacéutica, formulación farmacéutica combinada y kit de formulación combinada para la prevención o el tratamiento de la hepatitis B crónica, que comprende cada uno, como ingrediente activo, un agente antiviral oral y una vacuna terapéutica que incluye un lipopéptido y un adyuvante poli(I:C) | |
| KR20180052761A (ko) | T-dm1 불응성 암 환자의 syd985 치료 | |
| JP2004002481A5 (https=) | ||
| WO2005084387A3 (en) | Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer | |
| CN120826242A (zh) | 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途 | |
| JPH0455172B2 (https=) | ||
| Mandanas et al. | Phase II trial of cimetidine in metastatic melanoma: A Hoosier Oncology Group trial | |
| CN119677533A (zh) | 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合 | |
| Navarro et al. | American Association for Cancer Research (AACR)-106th Annual Meeting. Philadelphia, Pennsylvania, USA-April 18-22, 2015 |